Clinical Trial Update: MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating whether adding MGCD290 to fluconazole improves outcomes versus fluconazole alone for moderate to severe vulvovaginal candidiasis; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Fluconazole (Fluconazole)
• MGCD290 (MGCD290)

Snippet

Sponsor: MethylGene Inc. | Conditions: Vulvovaginal Candidiasis | Phase 2 | Status: COMPLETED